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analysis was performed with the Mainland-Gart test and
the Fisher exact test. Subjects were also asked to ﬁll out
a generic QoL questionnaire (the Functional Assessment
of Cancer Therapy-General [FACT-G]) at the beginning
of each cycle and on day 14 with the Subject Outcome
Questionnaire (SOQ), which evaluates levels of pain, dis-
comfort, inconvenience, satisfaction, etc. RESULTS: Of
the 76 randomised patients, 74 took study medication, 4
discontinued, making a total of 70 evaluable subjects.
Overall, 58 patients preferred pegﬁlgrastim (83%; p <
0.001) after 2 cycles. Signiﬁcantly more patients preferred
pegﬁlgrastim when starting with ﬁlgrastim ﬁrst (94%
versus 73%, p < 0.001), indicating a clear sequential
effect. The main reason for the overall preference of peg-
ﬁlgrastim was dosing simpliﬁcation, safety and less pain.
Overall, mean SOQ scores were better in the pegﬁlgras-
tim arm (87.5% versus 78.9% in the ﬁlgrastim arm, p <
0.05). Differences in speciﬁc SOQ areas were predomi-
nantly found in the pegﬁlgrastim arm. FACT-G scores
showed no signiﬁcant differences between treatment arms
and cycles. CONCLUSION: Subjects demonstrated a
very strong preference for pegﬁlgrastim (83%), primarily
because of dosing simpliﬁcation. A higher proportion also
reported less pain, discomfort and inconvenience, as well
as greater treatment satisfaction.
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OBJECTIVES: Treatment Outcomes in Pain Survey
(TOPS) characterizes pain and health-related quality of
life (HRQL) with chronic nonmalignant pain (CNMP).
TOPS has 8 subscales from SF-36 Health Survey and 14
TOPS domains measuring physical, functional, and psy-
chosocial status. We evaluated TOPS in cancer-related
pain. METHODS: TOPS was administered to 150
patients with advanced cancer-related pain at three US
academic hospitals. Data were collected on demographic
variables, primary site of cancer, and cancer treatment
status. Pain was measured on a visual analogue scale.
Internal consistency reliability (Cronbach’s alpha) was
assessed for the 8 TOPS SF-36 subscales and 14 TOPS
domains. Cases were compared by treatment status, phys-
iologic sources of pain, and pain severity using Student-t
tests and the Mann-Whitney U tests. RESULTS: Physical,
functional, and psychosocial status differed by treatment
status. There were no signiﬁcant differences in TOPS SF-
36 and TOPS domains for subjects experiencing neuro-
pathic compared to non-neuropathic pain. However,
those with somatic pain reported greater Body Pain (p =
0.001) and Pain Symptoms (p < 0.05), and had worse
Total Pain Experience (p < 0.05). Greater pain was asso-
ciated with signiﬁcantly poorer outcomes on 5 of the 8
SF-36 subscales, with more Pain Symptoms (p < 0.001),
greater family disruptions (p < 0.001), poorer Passive
Coping (p < 0.05), and less Patient Satisfaction with Out-
comes (p < 0.01). Reliability for SF-36 subscales and
TOPS domains were all > 0.70, similar to prior TOPS
usage in CNMP. CONCLUSIONS: TOPS demonstr-
ated acceptable reliability with cancer-related pain and
detected signiﬁcant differences by treatment status, 
source of pain, and pain severity. That TOPS SF-36 and
TOPS domains differed by pain severity supports its
validity as a measure to assess pain outcomes and HRQL
in cancer. TOPS may also be a useful clinical tool to 
identify patients at risk for impaired physical function,
symptoms, emotional distress, disruptions in social rela-
tionships, and negative perceptions of satisfaction with
health care.
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OBJECTIVE: To examine the association between hemo-
globin levels and anemia diagnosis and to determine the
hemoglobin level that is most likely to trigger diagnosis
in oncology patients. METHODS: Members of a large US
health plan with an oncology diagnosis and chemo-
therapy claims between January 1, 2002 and February
28, 2002 were included in this retrospective claims data-
base analysis. Medical and laboratory claims were exam-
ined to identify chemotherapeutic episodes, International
Classiﬁcation of Diseases 9th Modiﬁcation (ICD-9) codes
for anemia, and hemoglobin values within each episode
and immediately preceding new anemia diagnoses.
Descriptive statistics and multivariate regression were
used to examine the relationship between anemia diag-
nosis and hemoglobin values. RESULTS: A total of 3180
chemotherapeutic episodes corresponding to 2717 oncol-
ogy patients were identiﬁed. In episodes in which the
hemoglobin dropped below 12g/dL (1689 episodes;
53%), an anemia diagnosis occurred in only 733 episodes
(45%). Additionally, an anemia diagnosis was found in
only 66% of the episodes where hemoglobin fell below
10.0g/dL. Being over 50 years old, having Non-Hodgkins
Lymphoma, and having fatigue or renal disease were
observed to increase the odds of diagnosis controlling for
hemoglobin nadir values and chemotherapeutic agent.
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Adjusting for age above 50 years old, gender and breast
cancer, the mean hemoglobin value prior to anemia 
diagnosis was 11.2g/dL (95% CI; 11.0, 11.3). CON-
CLUSION: These data suggest that many patients who
become anemic during chemotherapy (≥Grade 1 anemia)
do not receive an anemia diagnosis. At hemoglobin values
below 10g/dL, the level at which the National Compre-
hensive Cancer Network (NCCN) most strongly recom-
mends consideration of aggressive anemia treatment, only
two-thirds of patients were identiﬁed as anemic by an
ICD-9 code. Our ﬁndings provide evidence that identify-
ing patients with ICD-9 codes for anemia from claims
data may be misleading and can signiﬁcantly underesti-
mate the true number of patients with anemia.
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OBJECTIVE: Chemotherapy-induced anemia is a
concern in oncology patients. The objective of this study
was to assess patterns of treatment with erythropoietic
therapy among oncology patients in a managed care
setting, and compare with the National Comprehensive
Cancer Network (NCCN) cancer and treatment-related
anemia clinical practice guideline recommendations.
METHODS: Members of a health plan who received
chemotherapy and erythropoietin and had access to lab-
oratory result data between January 1, 2002 and Febru-
ary 28, 2002 were included. Data were analyzed to
examine factors that were signiﬁcantly associated with
use of erythropoietic therapy stratiﬁed by nadir hemo-
globin categories. RESULTS: A total of 2560 patients
were identiﬁed. Erythropoietic therapy was initiated in
615 (45%) patients whose hemoglobin dropped below 12
g/dL, 443 (52%) patients whose hemoglobin dropped
below 11g/dL (NCCN hemoglobin level to consider ery-
thropoietic therapy), and 275 (62.5%) patients whose
hemoglobin dropped below 10g/dL (NCCN hemoglobin
level to strongly consider erythropoietic therapy). Multi-
variate analysis revealed that the mean probability of
receiving erythropoietic therapy was 0.34 (95% CI;
0.27–0.42) for patients whose hemoglobin fell between
10.5g/dL and 10.9g/dL; 0.44 (0.36–0.53) for patients
who reached a low between 10.0g/dL and 10.4g/dL; and
0.67 (0.61–0.72) for patients who dropped below 10.0
g/dL controlling for cancer type, blood administration, ﬁl-
grastim and select chemotherapeutic usage, hypertension
and diagnosis of anemia. Patients who received erythro-
poietic therapy were initiated following a mean adjusted
hemoglobin of 10.4g/dL (10.3g/dL–10.6g/dL). CON-
CLUSIONS: These data suggest a treatment gap in
patients whose hemoglobin levels drop below thresholds
set by the NCCN guidelines.
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Haemophilia treatment is very expensive and therapy has
to be life-long. In comparison with other diseases—e.g.,
diabetes—haemophilia is rare occurring in approximately
1 :10,000. OBJECTIVE: To determine the incremental
cost-effectiveness of prophylactic treatment compared
with on-demand treatment in patients with haemophilia
over a 1-year period from the third-party payers’ per-
spective. METHODS: A decision-tree model was devel-
oped to compare clinical outcomes, quality-adjusted life
years, and costs of prophylactic vs. on-demand treatment
for three European countries: Germany, Sweden, and the
United Kingdom. The time horizon of the decision-
analytic model was one year. Health effects were pre-
sented in terms of quality-adjusted life years gained
(QALYs) and in avoided bleeds as clinical outcome.
RESULTS: A total of 506 patients were included. Incre-
mental cost-effectiveness ratio (ICER) for prophylactic
treatment in one year for HIV-infected patients younger
than 30 years ranged from €1.24 million/QALY
(Germany) to €1.73 million/QALY (United Kingdom).
For Sweden, the ICER could not be calculated, because
all patients younger than 30 received prophylactic treat-
ment. For HIV-negative patients younger than 30 years,
ICER ranged from €2.21 million/QALY (Germany) to
€3.10 million/QALY (UK). These values were higher than
in the HIV-infected group, because the incremental effec-
tiveness of prophylactic treatment was smaller in HIV-
negative patients. In patients older than 30 years, ICERs
were even higher in HIV-negative patients, ranging from
€4.77 million/QALY (Germany) to €5.7 million/QALY
(Sweden and UK). In HIV-infected persons older than 30,
on-demand treatment dominates prophylactic treatment.
Prophylactic treatment was more expensive but yielded
slightly lower QALY values. CONCLUSION: Based on
our analysis and within the limitations of our short-term
model, prophylactic treatment has an extremely high
cost-effectiveness ratio when only a 1-year time horizon
is considered. Further research should focus on the long-
term consequences of the examined strategies.
